晚期男性乳腺癌的化疗
Chemotherapy for advanced male breast cancer.
作者信息
Yap H Y, Tashima C K, Blumenschein G R, Hortobagyi G N, Eckles N
出版信息
JAMA. 1980 May 2;243(17):1739-41.
PMID:7365938
Abstract
An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest that responsiveness of advanced male breast cancer to systemic chemotherapeutic agents is the same as that reported for advanced female breast cancer.
摘要
对18名晚期男性乳腺癌患者进行的29项化疗试验分析显示，总体缓解率为44%。这些化疗试验大多采用单药方案，即氟尿嘧啶、甲氨蝶呤、噻替派、环磷酰胺和美法仑。我们的数据表明，晚期男性乳腺癌对全身化疗药物的反应性与晚期女性乳腺癌的报告相同。
Zotero 插件